A microphysiological model of human MASLD reveals paradoxical response to resmetirom

1. Targher, G., Corey, K. E., Byrne, C. D. & Roden, M. The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. 18, 599–612 (2021).

   Google Scholar 

2. Wang, S. & Friedman, S. L. Found in translation—Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci. Transl. Med. 15, eadi0759 (2023).

   Google Scholar 

3. Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51–60 (2019).

   Google Scholar 

4. Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223 (2018).

   Google Scholar 

5. Green, C. J. et al. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm. Mol. Biol. Clin. Investig. https://doi.org/10.1515/hmbci-2018-0038 (2018).

6. Saydmohammed, M. et al. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. Exp. Biol. Med. 246, 2420–2441 (2021).

   Google Scholar 

7. Sakurai, Y., Kubota, N., Yamauchi, T. & Kadowaki, T. Role of insulin resistance in MAFLD. Int. J. Mol. Sci. 22, 4156 (2021).

   Google Scholar 

8. Najjar, S. M. & Perdomo, G. Hepatic insulin clearance: mechanism and physiology. Physiology 34, 198–215 (2019).

   Google Scholar 

9. Ter Horst, K. W. et al. Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease. Diabetes Care 44, 489–498 (2021).

   Google Scholar 

10. Bell, C. C. et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci. Rep. 6, 25187 (2016).

    Google Scholar 

11. Aizenshtadt, A. et al. Pump-Less, recirculating organ-on-chip (rOoC) platform to model the metabolic crosstalk between islets and liver. Adv. Healthc. Mater. 13, 2303785 (2024).

    Google Scholar 

12. Rigual, M. d. M. et al. Macrophages harness hepatocyte glutamate to boost liver regeneration. Nature 641, 1005–1016 (2025).

13. Wang, J., Wu, X., Zhao, J., Ren, H. & Zhao, Y. Developing liver microphysiological systems for biomedical applications. Adv. Healthc. Mater. 13, 2302217 (2024).

    Google Scholar 

14. Messelmani, T. et al. Liver organ-on-chip models for toxicity studies and risk assessment. Lab Chip 22, 2423–2450 (2022).

    Google Scholar 

15. Kostrzewski, T. et al. A microphysiological system for studying nonalcoholic steatohepatitis. Hepatol. Commun. 4, 77–91 (2020).

    Google Scholar 

16. Reaven, G. M. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988).

    Google Scholar 

17. Sarkar, U. et al. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab. Dispos. 43, 1091–1099 (2015).

    Google Scholar 

18. Tsamandouras, N. et al. Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. J. Pharmacol. Exp. Ther. 360, 95–105 (2017).

    Google Scholar 

19. Vacca, M. et al. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. Nat. Metab. 2, 514–531 (2020).

    Google Scholar 

20. Long, T. J. et al. Modeling therapeutic antibody-small molecule drug-drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab. Dispos. 44, 1940–1948 (2016).

    Google Scholar 

21. Clark, A. et al. A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties. Lab Chip. 17, 156–168 (2017).

22. Vaupel, P. & Multhoff, G. Blood supply and oxygenation status of the liver: from physiology to malignancy. In Oxygen Transport to Tissue XLIII. 263–267 (Springer International Publishing, Cham, 2022).

23. Domansky, K. et al. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10, 51–58 (2010).

    Google Scholar 

24. Rubiano, A. et al. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation. Clin. Transl. Sci. https://doi.org/10.1111/cts.12969 (2020).

25. Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497–509 (2024).

    Google Scholar 

26. Song, S. H. et al. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J. Clin. Endocrinol. Metab. 85, 4491–4499 (2000).

    Google Scholar 

27. Porksen, N. et al. Human insulin release processes measured by intraportal sampling. Am. J. Physiol. Endocrinol. Metab. 282, E695–E702 (2002).

    Google Scholar 

28. Kiselyov, V. V., Versteyhe, S., Gauguin, L. & De Meyts, P. Harmonic oscillator model of the insulin and IGF1 receptors’ allosteric binding and activation. Mol. Syst. Biol. 5, 243 (2009).

    Google Scholar 

29. Hori, S. S., Kurland, I. J. & DiStefano, J. J. 3rd Role of endosomal trafficking dynamics on the regulation of hepatic insulin receptor activity: models for Fao cells. Ann. Biomed. Eng. 34, 879–892 (2006).

    Google Scholar 

30. Matsumoto, M., Pocai, A., Rossetti, L., DePinho, R. A. & Accili, D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metabolism 6, 208–216 (2007).

    Google Scholar 

31. Li, T. et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J. Biol. Chem. 287, 1861–1873 (2012).

    Google Scholar 

32. Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411–428 (2019).

    Google Scholar 

33. Mittendorfer, B. Sexual dimorphism in human lipid metabolism. J. Nutr. 135, 681–686 (2005).

    Google Scholar 

34. Jamalinia, M., Lonardo, A. & Weiskirchen, R. Sex and gender differences in liver fibrosis: pathomechanisms and clinical outcomes. Fibrosis 2, 10006 (2024).

    Google Scholar 

35. Kimura, M. et al. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH. Cell 185, 4216–4232. e16 (2022).

    Google Scholar 

36. You, S. et al. Intravital imaging by simultaneous label-free autofluorescence-multiharmonic microscopy. Nat. Commun. 9, 2125 (2018).

    Google Scholar 

37. Liu, K. et al. Deep and dynamic metabolic and structural imaging in living tissues. Sci. Adv. 10, eadp2438 (2024).

    Google Scholar 

38. Stéphenne, X., Najimi, M. & Sokal, E. M. Hepatocyte cryopreservation: is it time to change the strategy? World J. Gastroenterol. 16, 1 (2010).

    Google Scholar 

39. Khetani, S. R. et al. Microengineered liver tissues for drug testing. J. Lab. Autom. 20, 216–250 (2015).

    Google Scholar 

40. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 1–14 (2013).

    Google Scholar 

41. Su, A. I. et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 101, 6062–6067 (2004).

    Google Scholar 

42. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).

    Google Scholar 

43. Ashburner, M. et al. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).

    Google Scholar 

44. Grissa, D., Junge, A., Oprea, T. I. & Jensen, L. J. Diseases 2.0: a weekly updated database of disease–gene associations from text mining and data integration. Database. https://doi.org/10.1093/database/baac019 (2022).

45. Piñero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48, D845–D855 (2019).

    Google Scholar 

46. Keenan, A. B. et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 47, W212–W224 (2019).

    Google Scholar 

47. Cadavid, J. L., Meimetis, N., Griffith, L. G. & Lauffenburger, D. A. Systems biology framework for rational design of operational conditions for in vitro / in vivo translation of microphysiological systems. Preprint at bioRxiv https://doi.org/10.1101/2025.01.17.633624 (2025).

48. Kostrzewski, T. et al. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun. Biol. 4, 1080 (2021).

    Google Scholar 

49. Hoang, S. A. et al. Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease. Sci. Rep. 9, 12541 (2019).

    Google Scholar 

50. Feaver, R. E. et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight 1, e90954 (2016).

    Google Scholar 

51. Cariou, B. et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr. Metab. 8, 1–6 (2011).

    Google Scholar 

52. Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M. & Trauner, M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65, 350–362 (2017).

    Google Scholar 

53. Schott, C. et al. GAS6 and AXL promote insulin resistance by rewiring insulin signaling and increasing insulin receptor trafficking to endosomes. Diabetes 73, 1648–1661 (2024).

    Google Scholar 

54. Tian, T. et al. Dietary quality and relationships with metabolic dysfunction-associated fatty liver disease (MAFLD) among United States adults, results from NHANES 2017–2018. Nutrients 14, 4505 (2022).

    Google Scholar 

55. Beygi, M., Ahi, S., Zolghadri, S. & Stanek, A. Management of metabolic-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: from medication therapy to nutritional interventions. Nutrients 16, 2220 (2024).

    Google Scholar 

56. Marino, L., Kim, A., Ni, B. & Celi, F. S. Thyroid hormone action and liver disease, a complex interplay. Hepatology 81, 651–669 (2025).

    Google Scholar 

57. Li, J., Ayada, I. & Pan, Q. Resmetirom directly inhibits lipid accumulation in human liver-derived organoids. J. Hepatol. 83, e86–e87 (2025).

58. Kannt, A. et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br. J. Pharmacol. 178, 2412–2423 (2021).

    Google Scholar 

59. Wang, X., Wang, L., Geng, L., Tanaka, N. & Ye, B. Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-κB signaling pathways in an RGS5-dependent manner. Int. J. Mol. Sci. 24, 5843 (2023).

    Google Scholar 

60. Polyzos, S. A. & Targher, G. Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis. Diabetes Obes. Metab. 27, 1635–1647 (2025).

    Google Scholar 

61. Rius-Pérez, S., Torres-Cuevas, I., Millán, I., Ortega, ÁL. & Pérez, S. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid. Med. Cell. Longev. 2020, 1452696 (2020).

    Google Scholar 

62. Zou, X. et al. Manganese superoxide dismutase (SOD2): is there a center in the universe of mitochondrial redox signaling? J. Bioenerg. Biomembr. 49, 325–333 (2017).

    Google Scholar 

63. Caro, J. F. et al. Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J. Clin. Invest. 78, 249–258 (1986).

    Google Scholar 

64. Koh, H. E., Cao, C. & Mittendorfer, B. Insulin clearance in obesity and type 2 Diabetes. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23020596 (2022).

65. Duriez, M. et al. A 3D human liver model of nonalcoholic steatohepatitis. J. Clin. Transl. Hepatol. 8, 359–370 (2020).

    Google Scholar 

66. Kozyra, M. et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci. Rep. 8, 14297 (2018).

    Google Scholar 

67. Cordero-Herrera, I. et al. AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis. Proc. Natl. Acad. Sci. USA 116, 217–226 (2019).

    Google Scholar 

68. Davidson, M. D., Pickrell, J. & Khetani, S. R. Physiologically inspired culture medium prolongs the lifetime and insulin sensitivity of human hepatocytes in micropatterned co-cultures. Toxicology 449, 152662 (2021).

    Google Scholar 

69. Sarkar, U. et al. Integrated assessment of diclofenac biotransformation, pharmacokinetics, and omics-based toxicity in a three-dimensional human liver-immunocompetent coculture system. Drug Metab. Dispos. 45, 855–866 (2017).

    Google Scholar 

70. Jang, K. J. et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aax5516 (2019).

71. Otumala, A. E. et al. Opportunities and considerations for studying liver disease with microphysiological systems on a chip. Lab Chip 23, 2877–2898 (2023).

    Google Scholar 

72. Yang, J. et al. Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease. Commun. Biol. 6, 310 (2023).

    Google Scholar 

73. Ströbel, S. et al. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. Sci Rep. 11, 22765 (2021). Nov 23.

    Google Scholar 

74. Youhanna, S. et al. Chemogenomic screening in a patient-derived 3D fatty liver disease model reveals the CHRM1-TRPM8 axis as a novel module for targeted intervention. Adv. Sci. 12, 2407572 (2025).

    Google Scholar 

75. Gorden, D. L. et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J. Lipid Res. 56, 722–736 (2015).

    Google Scholar 

76. McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148–1155 (2015).

    Google Scholar 

77. Liu, H. et al. Dissecting acute drug-induced hepatotoxicity and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-a-chip model. Adv. Sci. 11, 2403516 (2024).

    Google Scholar 

78. Lauschke, V. M., Hendriks, D. F., Bell, C. C., Andersson, T. B. & Ingelman-Sundberg, M. Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem. Res. Toxicol. 29, 1936–1955 (2016).

    Google Scholar 

79. Lopez-Alcantara, N., Oelkrug, R., Sentis, S. C., Kirchner, H. & Mittag, J. Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression. Iscience 26, 108064 (2023).

    Google Scholar 

80. Xia, M. et al. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy. Front. Cell Dev. Biol. 12, 1423936 (2024).

    Google Scholar 

81. Ezhilarasan, D. Thyromimetics and MASLD: unveiling the novel molecules beyond resmetirom. J. Gastroenterol. Hepatol. 40, 367–378 (2025).

82. Satin, L. S., Butler, P. C., Ha, J. & Sherman, A. S. Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol. Aspects Med. 42, 61–77 (2015).

    Google Scholar 

83. Laurenti, M. C. et al. Diabetes-associated genetic variation in TCF7L2 alters pulsatile insulin secretion in humans. JCI Insight. https://doi.org/10.1172/jci.insight.136136 (2020).

84. Bauer, S. et al. Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model. Sci Rep. 7, 14620 (2017).

    Google Scholar 

85. Inzucchi, S. E. et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149 (2015).

    Google Scholar 

86. Hodson, L., Skeaff, C. M. & Fielding, B. A. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog. Lipid Res. 47, 348–380 (2008).

    Google Scholar 

87. Groop, L., Widen, E. & Ferrannini, E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 36, 1326–1331 (1993).

    Google Scholar 

88. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 29, e45–e45 (2001).

    Google Scholar 

89. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).

    Google Scholar 

90. Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).

    Google Scholar 

91. Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom. Bioinform. 2, lqaa078 (2020).

    Google Scholar 

92. Weigelin, B., Bakker, G.-J. & Friedl, P. Third harmonic generation microscopy of cells and tissue organization. J. Cell Sci. 129, 245–255 (2016).

    Google Scholar 

93. Georgakoudi, I. & Quinn, K. P. Label-free optical metabolic imaging in cells and tissues. Ann. Rev. Biomed. Eng. 25, 413–443 (2023).

    Google Scholar 

94. Hellen, D. J. & Karpen, S. J. LiverQuant: an improved method for quantitative analysis of liver pathology. Bio-Protoc. 13, e477 (2023).

    Google Scholar 

95. Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 1–7 (2017).

    Google Scholar 

Download references